文献速递乳腺MR

基于瘤内微生物组相关MRI模型预测乳腺癌新辅助治疗后的肿瘤缩小模式

Intratumoral Microbiome-related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy.
PubMed 文献 · Radiology · 2025-01-01

这项回顾性研究纳入12家机构2015年7月至2023年4月接受新辅助治疗并手术的乳腺癌患者,开发融合瘤内微生物组数据与MRI影像组学/深度学习的模型预测肿瘤缩小模式。融合模型在内部验证集AUC为0.89,外部验证集AUC为0.87,优于单时间点模型,且在分子亚型和肿瘤分期中保持稳健。

要点

  • 融合模型在外部验证集预测肿瘤缩小模式的AUC为0.87,优于单时间点模型的0.74-0.81。
  • 同心性缩小患者的瘤内微生物丰度较高(P < .001)。
  • 融合模型在不同分子亚型(AUC 0.85-0.91)和肿瘤分期(AUC 0.84-0.89)中表现稳健。

核心结论

  • 基于瘤内微生物组的MRI模型能够精确预测乳腺癌新辅助治疗后的肿瘤缩小模式。

研究设计与样本

  • 回顾性研究,纳入12家机构2015年7月至2023年4月接受新辅助治疗并手术的乳腺癌患者2249例,分为训练集671例、内部验证集335例和外部验证集1243例,收集新辅助治疗前和治疗中MRI,开发5种整合三维U-Net自动分割、生境影像组学和/或深度学习(ResNet-50)特征及组织学瘤内微生物组数据的模型。

关键影像表现/征象

  • 1238例(55%)患者发生同心性缩小,同心性缩小肿瘤的微生物丰度增加(P < .001)。
  • 三维U-Net在新辅助治疗前MRI上的Dice系数在训练集、内部验证集和外部验证集分别为0.96、0.92、0.91。
  • 三维U-Net在新辅助治疗中MRI上的Dice系数在训练集、内部验证集和外部验证集分别为0.96、0.90、0.88。
  • Shapley加性解释确认每个影像特征均独立预测肿瘤缩小模式。

诊断标准与关键数值

  • 融合模型在内部验证集预测肿瘤缩小模式的AUC为0.89,优于单时间点模型的0.80-0.83(所有P < .05)。
  • 融合模型在外部验证集预测肿瘤缩小模式的AUC为0.87,优于单时间点模型的0.74-0.81(所有P < .001)。
  • 融合模型在不同分子亚型中AUC范围为0.85-0.91,在不同肿瘤分期中AUC范围为0.84-0.89。

临床应用与阅片要点

  • 模型整合新辅助治疗前和治疗中MRI特征及瘤内微生物组数据,用于预测乳腺癌新辅助治疗后的肿瘤缩小模式。
  • 三维U-Net自动分割在新辅助治疗前和治疗中MRI上均表现出较高的Dice系数。
  • Shapley加性解释可用于解读模型输出中每个影像特征的独立预测贡献。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Patients with breast cancer exhibit different tumor shrinkage patterns (TSPs) after neoadjuvant therapy (NAT), making accurate TSP prediction essential for breast-conserving surgery planning. The intratumoral microbiome influences treatment response, and related imaging features may improve TSP prediction. Purpose To develop an intratumoral microbiome-related MRI model that accurately predicts TSP following NAT. Materials and Methods This retrospective study included patients with breast cancer who underwent NAT followed by surgery at 12 institutions between July 2015 and April 2023. Patients were allocated to training (n = 671), internal validation (n = 335), and external validation (n = 1243) sets. Pre-NAT and mid-NAT MRI scans were collected for model development and validation. Five models integrating three-dimensional U-Net automated segmentation, habitat radiomic and/or deep learning (ResNet-50) features, and histologic intratumoral microbiome data were developed: pre-NAT habitat, mid-NAT habitat, pre-NAT ResNet-50, mid-NAT ResNet-50, and a fusion model. Models were validated across molecular subtypes and tumor stages using receiver operating characteristic curves, confusion matrices, and diagnostic metrics. Shapley additive explanations were used to interpret model output. Results Among 2249 women with breast cancer (median age, 49 years [IQR, 42-56 years]), 1238 (55%) experienced concentric shrinkage. Tumors with concentric shrinkage had increased microbiome abundance (P < .001). The three-dimensional U-Net achieved Dice coefficients of 0.96, 0.92, and 0.91 on pre-NAT MRI scans and 0.96, 0.90, and 0.88 on mid-NAT MRI scans in the training, internal validation, and external validation sets, respectively. The fusion model outperformed single-time point models in the internal validation set (area under the receiver operating characteristic curve [AUC], 0.89 vs 0.80-0.83; all P < .05) and external validation set (AUC, 0.87 vs 0.74-0.81; all P < .001), remaining robust across molecular subtypes (AUC range, 0.85-0.91) and tumor stages (AUC range, 0.84-0.89). Shapley additive explanations confirmed that each imaging feature independently predicted TSP. Conclusion An intratumoral microbiome-related MRI model enabled precise TSP prediction. © The Author(s) 2025. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Huang Y, Song X, Chen Y, et al. Intratumoral Microbiome-related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy. Radiology. 2025. PMID: 40892452. doi:10.1148/radiol.243545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。